Search through
Carvedilol is a non-selective beta-adrenergic receptor blocker with additional alpha-1 blocking activity, universally utilised for managing hypertension, heart failure, and post-myocardial infarction conditions. Carvedilol reduces heart rate, blood pressure, and myocardial oxygen demand while improving left ventricular function. Also referred to as Carvedilol Hydrochloride and Carvedilolum, it demonstrates high oral bioavailability, effective receptor binding, metabolic stability. We are the trusted Carvedilol USP supplier worldwide, ensuring reliable lead times and consistent API quality for pharmaceutical manufacturing and clinical research.
Carvedilol is a non-selective beta-adrenergic receptor blocker with additional alpha-1 blocking activity, universally utilised for managing hypertension, heart failure, and post-myocardial infarction conditions. Carvedilol reduces heart rate, blood pressure, and myocardial oxygen demand while improving left ventricular function. Also referred to as Carvedilol Hydrochloride and Carvedilolum, it demonstrates high oral bioavailability, effective receptor binding, metabolic stability. We are the trusted Carvedilol USP supplier worldwide, ensuring reliable lead times and consistent API quality for pharmaceutical manufacturing and clinical research.
Chemical Properties & Specifications
H411 (86.8%): Toxic to aquatic life with long lasting effects
P273, P391, and P501
Treatment of hypertension, chronic heart failure, post-myocardial infarction management.
Non-selective beta-blocking with alpha-1 adrenergic inhibition improves cardiovascular outcomes (remarkably)
Enables effective therapeutic dosing.
Maintains consistent plasma levels for extended periods.
Used in cardiovascular pharmacology studies & preclinical investigations on adrenergic receptors.
Store at 15–25°C (59–77°F)
Protect from moisture and light; keep in tightly sealed containers
Carvedilol is used to manage hypertension, heart failure, and post-myocardial infarction conditions.
It blocks beta-adrenergic receptors and alpha-1 receptors, reducing heart rate, blood pressure, and myocardial oxygen demand.
Typically ≥99% by HPLC assay.
Pharmaceutical API manufacturers, clinical research organizations, and formulation development companies.
Oral tablets and combination therapies with other cardiovascular agents.
Yes, Universally used in preclinical and clinical studies for cardiovascular pharmacology.
Available in kilogram quantities, with bulk supply options for pharmaceutical manufacturing.
